HeartSciences Showcases MyoVista® Wavelet ECG at the 2018 International Congress on Electrocardiology (ICE)
HeartSciences , an innovative medical device company, is proud to announce its participation as an exhibitor at the upcoming 2018 International Congress on Electrocardiology (ICE ), which will be held in Makuhari Messe, Chiba City, Japan, June 28-30, 2018. ICE2018 will be the joint meeting of the 45th Congress of the International Society of Electrocardiology (ISE) and the 18th Congress of the International Society for Holter and Noninvasive Electrocardiology (ISHNE ). This Congress will focus on Electrocardiography, from noninvasive diagnosis to prognosis covering basic electrophysiology, novel signal processing methods of Holter ECG, prognostic ECG techniques for preventing sudden cardiac death, applications of antiarrhythmic agents and direct oral anticoagulants, a critical role of catheter ablation for tachyarrhythmias and appropriate use of implantable devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180625005026/en/
HeartSciences is leading innovation in the field of electrocardiography through the application of continuous wavelet transform (CWT) signal processing and artificial intelligence. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista® Wavelet ECG (wav ECG™) is a first-to-market 12-lead resting electrocardiograph with new informatics based on wavelet signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to proprietary informatics, the MyoVista wav ECG Device has full 12-lead resting ECG capabilities including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training with no change in ECG clinical workflow. The MyoVista wav ECG Device is not currently FDA approved for commercial sale or distribution in the United States.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com .
The following link leads to a multimedia support platform designed to
provide rapid download of media elements needed to develop your story
about HeartSciences and MyoVista Technology.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-TRANSPHORM23.4.2019 10:02:10 CEST | Pressemeddelelse
Transphorm Centers on the Simplicity and Reliability of High Voltage GaN Application Development at PCIM 2019
PV-INFOLINK23.4.2019 09:02:13 CEST | Pressemeddelelse
PV InfoLink to Host Dialogues with Industry Heavyweights on 2H19 Solar Market Outlook Prior To SNEC
JPND23.4.2019 08:47:11 CEST | Pressemeddelelse
JPND Launches Updated Research and Innovation Strategy
WIN-CONSORTIUM22.4.2019 17:02:12 CEST | Pressemeddelelse
Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer
PA-PPG22.4.2019 16:15:08 CEST | Pressemeddelelse
PPG Advances Sustainability to Protect and Beautify the World
NY-MOODY'S/STANDARD-BANK22.4.2019 15:02:13 CEST | Pressemeddelelse
Standard Bank Moves Business to the Cloud with Moody’s Analytics
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum